Cargando…
Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221059/ http://dx.doi.org/10.1186/1471-2334-14-S2-S12 |
| _version_ | 1782342840596037632 |
|---|---|
| author | Stellbrink, Hans-Jürgen |
| author_facet | Stellbrink, Hans-Jürgen |
| author_sort | Stellbrink, Hans-Jürgen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4221059 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42210592014-11-10 Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons Stellbrink, Hans-Jürgen BMC Infect Dis Speaker Presentation BioMed Central 2014-05-23 /pmc/articles/PMC4221059/ http://dx.doi.org/10.1186/1471-2334-14-S2-S12 Text en Copyright © 2014 Stellbrink; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Speaker Presentation Stellbrink, Hans-Jürgen Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| title | Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| title_full | Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| title_fullStr | Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| title_full_unstemmed | Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| title_short | Should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| title_sort | should we avoid protease inhibitors in first lines due to their lipid side effects? - cons |
| topic | Speaker Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221059/ http://dx.doi.org/10.1186/1471-2334-14-S2-S12 |
| work_keys_str_mv | AT stellbrinkhansjurgen shouldweavoidproteaseinhibitorsinfirstlinesduetotheirlipidsideeffectscons |